MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. scores highest on Anchor (65) and lowest on Nitro (16). Its PosiPenta is 40.66 out of 100, around the middle of similar companies.
On the Penta Grid this week, MapLight Therapeutics, Inc. is Grid #520 of 837 in the Healthcare sector in United States, and Grid #2,824 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| MapLight Therapeutics, Inc. | 40.66 | 37 | 33 | 16 | 52 | 65 |
| Ovid Therapeutics Inc. | 52.31 | 29 | 40 | 71 | 60 | 62 |
| DiaMedica Therapeutics Inc. | 45.76 | 6 | 37 | 72 | 52 | 62 |
| Cerus Corporation | 46.44 | 11 | 74 | 64 | 43 | 40 |
| NeuroPace, Inc. | 36.12 | 1 | 62 | 61 | 16 | 41 |
| 908 Devices Inc. | 56.82 | 18 | 58 | 86 | 63 | 58 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -1.23 |
| P/B ratio | 1.23 |
EEarnings
| Trailing EPS | ₹-591.97 |
| Forward EPS | ₹-323.82 |
NNitro
| Price | 729.31 |
| 52-week high | 3829.33 |
| 52-week low | 706.57 |
| Fall from 52-week high | 81.0% |
TTorque
| Return on equity (ROE) | -111.55% |
| Debt-to-equity | 0.01 |
AAnchor
| Beta (price swings) | — |
| Market cap | ₹4,053 Cr |
| Insider holding | 52.27% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is MapLight Therapeutics, Inc.'s PosiPenta score?
MapLight Therapeutics, Inc.'s PosiPenta is 40.66 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does MapLight Therapeutics, Inc. stand on the Penta Grid?
On the Penta Grid this week, MapLight Therapeutics, Inc. is Grid #520 of 837 in the Healthcare sector in United States, and Grid #2,824 of 4,000 in United States.
Which PosiPenta pillar is strongest for MapLight Therapeutics, Inc.?
Anchor (stability and dividends), with a score of 65 out of 100: better than most similar companies.
Which PosiPenta pillar is weakest for MapLight Therapeutics, Inc.?
Nitro (momentum), with a score of 16 out of 100: much weaker than most similar companies.
Has MapLight Therapeutics, Inc.'s PosiPenta changed since last week?
Yes, it rose 2.61 points, from 38.05 to 40.66.
PositoAI is for research and education only and is not investment advice.